SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant investor interest following a major U.S. commercialization partnership with Tolmar and positive clinical trial progress across multiple oncology indications. The community is actively discussing the company's robust pipeline, significant de-risking milestones, and the disconnect between the stock's current price and its strong long-term growth potential.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending due to intense speculation surrounding an imminent buyout and the anticipation of the 80th clinical trial event. Investors are actively discussing the potential impact of institutional accumulation and the company's oncology pipeline, leading to high-conviction sentiment and debates over its valuation and regulatory path.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO Inc. is currently seeing significant volatility and intense discussion as investors navigate the final stages of the company's transformative acquisition of TopBuild. While some community members remain deeply bullish on Brad Jacobs' track record and the long-term potential for market dominance, others are expressing frustration over the stock's recent downward pressure, attributed by many to institutional short-selling, arbitrage activity, and market-wide macro concerns.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing intense scrutiny as investors grapple with leadership departures, high-profile insider selling, and concerns over the company's timeline for converting AI data center demand into sustainable revenue. While bulls highlight Navitas' participation in the NVIDIA MGX ecosystem and its next-generation power efficiency technology as drivers for long-term growth, the stock is experiencing significant volatility driven by concerns over potential dilution and sector-wide sentiment shifts.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is gaining market attention as investors speculate on the potential of its selective ITK inhibitor, soquelitinib, with community members actively discussing upcoming data readouts and potential partnership or acquisition opportunities. The stock is seeing heightened volatility as market participants debate the company's long-term pipeline value against ongoing short interest and recent institutional ownership shifts.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors weigh structural changes following record-sized IPO filings from major entities like SpaceX and Anthropic, alongside increased market volatility and discussions around 24/5 clearing infrastructure. The community is actively debating the implications of AI on traditional financial data providers, the potential impact of algorithmic market structures, and the broader macro environment affecting market liquidity.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares are under pressure as investors weigh competitive concerns regarding SpaceX's expansion into consumer wireless services against the company's dividend yield and long-term infrastructure investment. The community is actively debating whether current valuation levels represent a generational buying opportunity for income-focused portfolios or if broader shifts in the telecommunications sector warrant caution.

ASP Isotopes, Inc. is developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. It operates through the following segments: Nuclear Fuels, Specialist Isotopes and Related Services, and Helium and LNG. The Nuclear Fuels segment engages in the research and development of technologies and methods for producing HALEU and Lithium-6 for the advanced nuclear fuels target market, including the operations of QLE. The Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods for the separation of high-value, low-volume isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending as investors focus on imminent catalysts, including the highly anticipated spinoff of its nuclear fuel subsidiary, Quantum Leap Energy, and progress on critical helium and isotope production milestones. The community remains hyper-focused on the company's potential to supply advanced materials for the growing AI, semiconductor, and nuclear energy sectors, while actively debating the impact of recent insider activity and broader sector volatility.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following a post-earnings sell-off where investors reacted to moderate ARR growth despite strong revenue and a announced 4-for-1 stock split. The community remains divided, with some viewing the pullback as an attractive buying opportunity for a long-term cybersecurity leader, while others argue the stock remains fundamentally overvalued relative to its growth pace.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail and institutional investors anticipate near-term catalysts, including global expansion progress and revenue updates, while actively debating the stock's significant short interest and long-term potential in cancer immunotherapy. The community remains highly focused on upcoming news, the company's proprietary NK cell manufacturing platform, and potential developments in global markets like Saudi Arabia.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.

Amgen or Biogen: Which Biotech Stock Appears Better Poised?

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

Medicare will start covering obesity drugs for the first time. Here's what patients should know

The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors...

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

Here's Why Shares of Eli Lilly Hit an All-Time High on Friday

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.80	--	--	N/A
Q1 '26	$0.91	$1.04	14.35%	BEAT
Q4 '25	$0.93	$0.95	2.82%	BEAT
Q3 '25	$0.75	$0.69	-7.91%	MISSED
Q2 '25	$0.92	$0.93	1.42%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVONovo Nordisk A/S

Upcoming Earnings: Q2 '26

Historical Earnings

Latest NVO News